Denosumab biosimilar (Qilu Pharma)

地舒单抗生物类似药（齐鲁制药）

Report date: 2024/07/02 13:29:54

Base Information

Drug NameDenosumab biosimilar (Qilu Pharma)
Drug Alias Name地舒单抗生物仿制药（齐鲁制药）德尼单抗生物仿制药（齐鲁制药）迪诺舒单抗生物仿制药（齐鲁制药）鲁可欣QL-1206
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesSolid tumoursOsteoporosis, Postmenopausal +[4] 
Global Approved IndicationsOsteoporosis, Postmenopausal
Approved Indications in ChinaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryMainland China
Original Approved Date2023/09/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsBone metastasesSolid tumoursOsteoporosis, Postmenopausal +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeM05BX04
Related LinksN/A